Corgentech Inc. (CGTK)
Interview with: Richard P. Powers, Vice President and CFO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their pipeline of novel therapeutics based on proprietary TF Decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer.

Cover Story

CEOCFO Interview Index

CEOCFO Current Issue

Cover Story Archives

Future Features

Analyst Interviews

Corporate Financials

Archived Interviews
 
About CEOCFOinterviews.com

Contact & Ordering

This is a printer friendly page!

Corgentech’s E2F Decoy technology is now in the final stages of its Phase III trials.   It could be the first drug surgeons will be able to use for prevention of vein graft failure in heart bypass (CABG) and leg bypass (PBG) surgery.



Healthcare
Biotechnology & Drugs
(CGTK - Nasdaq)

Corgentech Inc.




Richard P. Powers
Vice President and
Chief Financial Officer

Interview conducted by:
Lynn Fosse
Senior Editor

CEOCFOinterviews.com
November 2004

To order the complete November 4, 2004 Issue of CEOCFOinterviews.com left click below for our secure forms:

Purchase NOW!

There is a $5.00 charge for each current issue!

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“Our drug is in the final development stage in two Phase III trials for a single indication of   ‘prevention of vein graft failure’. Our first trial is in leg surgery.   Here the vascular surgeon will use the greater saphenous vein to bypass clogged arteries in the leg, for patients who have leg pain at rest. That trial is fully enrolled with 1,400 patients in over eighty centers in the United States and we expect the results of that trial by the end of this year. The second trial is for cardiovascular arterial bypass graft (CABG) surgery has also completely enrolled all 2400 patients treated in over a hundred centers in the United States.  The data from that trial will be available in the first quarter of 2005. We have Fast Tack designation from the FDA for both indications due to the high unmet medical need, compelling pre-clinical data, excellent safety profile, and no other approved drugs. This designation could afford Corgentech a shorter, six month, review cycle to approval.” - Richard P. Powers

Newsflash!

To view Releases highlight & left click on the company name!